Genetic Modulation of Hypertrophic Cardiomyopathy Severity
肥厚型心肌病严重程度的基因调节
基本信息
- 批准号:9332400
- 负责人:
- 金额:$ 49.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-15 至 2020-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Variability in hypertrophic cardiomyopathy (HCM) clinical manifestation is primarily determined by modifier
genes, which are poorly understood. Discovering of the genetic basis of differential vulnerability is critical in
predictive and personalized care for patients with HCM and will enabling more comprehensive genetic and
genomic screening with an aim to intervene as early as possible and eliminate risk of sudden death. The
discovery of modifier genes that contribute to variation and incomplete penetrance of HCM has proven difficult
in human cohorts. Large murine genetic reference populations (GRPs) now finally provide a effective solution.
The BXD family of strains—currently the largest and best characterized mouse GRP—is made up of 160 highly
diverse lines that descend from crosses between C57BL/6J (B6) and DBA/2J (D2) parental strains. The BXDs
have been bred specifically for systems genetics studies using both classic forward genetic methods and for
reverse genetic studies. We have shown that the D2—father of the BXD cross—is an excellent murine HCM
model. D2 contains mutations of Mybpc3 and Myh7, the major causal genes of HCM and the key features of
human HCM. In contrast, the B6 (mother of the BXDs) has wild type alleles and normal hearts. The objective
of our proposal is to identify modifier genes that affect the severity of HCM phenotypes. Our hypothesis is that
interactions of modifier and causal genes govern HCM severity and related phenotypes. The research here
involves multi-scale genetic, transcriptomic, molecular and cellular profiling of B6, D2, and up to 100 BXDs.
This work will be transformative and lead to the identification of strong candidate genes and networks
underlying individual differences in HCM phenotypes. Aim 1: Systematically quantify HCM-associated traits
and their variability and heritability across 100 BXD genotypes of isogenic mice. The purpose of Aim 1 is to
determine the clinical, laboratory and molecular HCM phenotypes in 100 BXD strains, setting the stage for us
to explore genetic variation, cofactors, and mechanisms of HCM in Aims 2 and 3. Aim 2: Define genes that
modulate the severity of HCM. Building upon the phenotype data generated in Aim 1, as well as the already
acquired sequence and transcriptome data for B6 and D2, and BXDs, we will identify strong gene variants that
modulate variability of HCM phenotypes using state-of-the-art system genetic strategies and conventional
molecular and cellular assays. Aim 3: Test the translational validity of mouse HCM modifier gene candidates.
We will justify candidate genes identified in Aim 2 with established HCM human GWAS data. In reciprocal
reverse translation, we will evaluate candidate HCM genes from human cohorts and determine whether these
variants are associated with HCM-associated traits in BXDs. Combining the top priority gene candidates from
both mouse and human HCM studies, we will generate molecular and statistical models of susceptible
candidate genes, linked phenotypes, and relevant mechanisms. We will finally validate genes modulating HCM
phenotype severity using loss-off function strategy.
肥厚心肌病(HCM)临床表现的变异性主要由修饰符确定
基因,不理解。发现差异脆弱性的遗传基础至关重要
针对HCM患者的预测和个性化护理,将使更全面的遗传和
基因组筛查的目的是尽早干预并消除猝死的风险。
事实证明,发现有助于变异和不完整渗透率的修饰剂基因已被证明很困难
在人类同伙中。现在,大型鼠遗传参考人群(GRP)最终提供了有效的解决方案。
BXD菌株家族(目前是最大,最佳的鼠标GRP)由160个高度组成
从C57BL/6J(B6)和DBA/2J(D2)父母菌株之间的十字架下降的潜水线。 BXD
已经专门针对使用经典远期遗传学方法的系统遗传学研究而繁殖
反向遗传研究。我们已经表明,D2(BXD十字架的父亲)是一个出色的鼠HCM
模型。 D2包含MYBPC3和MYH7的突变,HCM的主要休闲基因和关键特征
人类HCM。相比之下,B6(BXD的母亲)具有野生型等位基因和正常心脏。目标
我们的建议是确定影响HCM表型严重程度的修饰基因。我们的假设是
修饰符和因果基因的相互作用控制HCM严重程度和相关表型。这里的研究
涉及B6,D2和多达100 BXD的多尺度遗传,转录组,分子和细胞分析。
这项工作将具有变革性,并导致识别强候选基因和网络
HCM表型中的个体差异。 AIM 1:系统量化与HCM相关的性状
以及它们在100 BXD基因型的异源小鼠中的可变性和遗传力。目标1的目的是
确定100个BXD菌株中的临床,实验室和分子HCM表型,为我们奠定了阶段
探索目标2和3中HCM的遗传变异,辅助因子和机制。目标2:定义基因
调节HCM的严重程度。基于AIM 1中生成的表型数据以及已经
获得了B6和D2以及BXD的获取序列和转录组数据,我们将确定强大的基因变异
使用最先进的系统遗传策略和常规的系统调节HCM表型的变异性
分子和细胞测定。 AIM 3:测试小鼠HCM修饰符基因候选物的翻译有效性。
我们将证明具有既定的HCM人类GWAS数据在AIM 2中确定的候选基因合理。在倒数中
反向翻译,我们将评估来自人类人群的候选HCM基因,并确定这些是否是否
变体与BXD中的HCM相关性状有关。结合最高优先基因候选者
小鼠和人类HCM研究,我们将生成易感的分子和统计模型
候选基因,连接的表型和相关机制。我们最终将验证调制HCM的基因
使用损失功能策略的表型严重程度。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
LU LU的其他基金
Discovery of modifier genes in cardiomyopathy
心肌病修饰基因的发现
- 批准号:1060009910600099
- 财政年份:2020
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Genetic and Environmental Determinants of GPRC6A Regulation of Energy Metabolism Using Genetically Engineered Mice and Systems Biology
GPRC6A 能量代谢调节的遗传和环境决定因素利用基因工程小鼠和系统生物学
- 批准号:1054449810544498
- 财政年份:2020
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Genetic and Environmental Determinants of GPRC6A Regulation of Energy Metabolism Using Genetically Engineered Mice and Systems Biology
GPRC6A 能量代谢调节的遗传和环境决定因素利用基因工程小鼠和系统生物学
- 批准号:1032074410320744
- 财政年份:2020
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Discovery of modifier genes in cardiomyopathy
心肌病修饰基因的发现
- 批准号:1039747510397475
- 财政年份:2020
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Genetic Modulation of Hypertrophic Cardiomyopathy Severity
肥厚型心肌病严重程度的基因调节
- 批准号:91737109173710
- 财政年份:2016
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Genetic Analysis of Ethanol-Mediated Stress Reduction
乙醇介导的减压的遗传分析
- 批准号:70712877071287
- 财政年份:2004
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Genetic Analysis of Ethanol-Mediated Stress Reduction
乙醇介导的减压的遗传分析
- 批准号:72405077240507
- 财政年份:2004
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Genetic Analysis of Ethanol-Mediated Stress Reduction
乙醇介导的减压的遗传分析
- 批准号:67835116783511
- 财政年份:2004
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Genetic Analysis of Ethanol-Mediated Stress Reduction
乙醇介导的减压的遗传分析
- 批准号:74339447433944
- 财政年份:2004
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Genetic Analysis of Ethanol-Mediated Stress Reduction
乙醇介导的减压的遗传分析
- 批准号:68987876898787
- 财政年份:2004
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
相似国自然基金
等位基因聚合网络模型的构建及其在叶片茸毛发育中的应用
- 批准号:32370714
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于等位基因非平衡表达的鹅掌楸属生长量杂种优势机理研究
- 批准号:32371910
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
基于人诱导多能干细胞技术研究突变等位基因特异性敲除治疗1型和2型长QT综合征
- 批准号:82300353
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ACR11A不同等位基因调控番茄低温胁迫的机理解析
- 批准号:32302535
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
肠杆菌多粘菌素异质性耐药中phoPQ等位基因差异介导不同亚群共存的机制研究
- 批准号:82302575
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Project 3: Therapeutic Gene Editing for Huntington's Disease
项目3:亨廷顿病的治疗性基因编辑
- 批准号:1066876910668769
- 财政年份:2023
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Activity-Dependent Regulation of CaMKII and Synaptic Plasticity
CaMKII 和突触可塑性的活动依赖性调节
- 批准号:1081751610817516
- 财政年份:2023
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Enabling AI-based Mouse Genetic Discovery
实现基于人工智能的小鼠基因发现
- 批准号:1072452210724522
- 财政年份:2023
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Leveraging CRISPR RNA-guided DNA Transposases for Gene Insertion at the CFTR Locus
利用 CRISPR RNA 引导的 DNA 转座酶在 CFTR 基因座插入基因
- 批准号:1060669810606698
- 财政年份:2023
- 资助金额:$ 49.8万$ 49.8万
- 项目类别:
Bacterial CRISPR interference to define macrophage responses to group B Streptococcus proteins
细菌 CRISPR 干扰定义巨噬细胞对 B 族链球菌蛋白的反应
- 批准号:1072460710724607
- 财政年份:2023
- 资助金额:$ 49.8万$ 49.8万
- 项目类别: